AIDS 2006 News

• Making prevention work: interventions with gay men
• Making prevention work: abstinence and partner reduction reviewed at World AIDS conference
• HIV surveillance at immunisation clinics reveals weakness in KwaZulu Natal's PMTCT programme
• Safer crack-smoking resources as a viable addition to comprehensive harm reduction programs for reducing HIV and HCV transmission
• Awareness and use of HIV pre-exposure prophylaxis (PrEP) are found to be low in San Francisco gay and bisexual men
• Many HIV-positive patients in London risking their health by use of alternative therapies
• Needle-free mode of T-20 dosing looks highly satisfactory for patients
• SMART study - treatment breaks lower quality of life
• AZT/3TC before and after labour reduces HIV transmission whether infants fed with formula or breastfed and weaned early
• Splitting Triomune tablets for children: smallest get poorest nevirapine dose
• Gay men, methamphetamine and HIV: some issues explored at the Toronto conference
• Stress increases sexual risk-taking and risk of HIV for gay men
• Patients who need HIV therapy in London are accessing it, regardless of ethnicity or sexuality
• India's HIV prevalence has been 'grossly overestimated'
• Alphabet of prevention technologies expanding, but no 'magical solution'
• Sexually transmitted infections increase HIV risk for gay men
• Extensively drug-resistant TB rapidly fatal in South Africa
• HIV/HCV coinfected patients more prone to end-stage liver disease without treatment
• Over 40% of HIV-infected gay men in UK unaware of status; more than half believe they are HIV-negative
• Is Uganda's HIV prevention success story 'unravelling'?
• Botswana’s adult HIV mortality rate falls since the rollout of free antiretroviral therapy
• Is serosorting working, or even possible?
• Pre-exposure prophylaxis ‘would be cost-effective’ if more than 50% efficacious
• The limits of PEP: saturation knowledge does not mean saturation use
• MK-0518 integrase inhibitor effective in treatment-naive patients
• Access to treatment associated with declining stigma in Botswana
• Maraviroc raises CD4 counts in patients with mixed-tropism virus, may offer value for highly treatment-experienced
• Vicriviroc effective in treatment-experienced patients, but malignancy questions remain unanswered
• TNX-355, new entry inhibitor, effective in highly treatment-experienced patients
• Efavirenz more durable than Kaletra over two years in treament-naive patients
• Kaletra monotherapy as effective as triple therapy for at least 18 months
• Merck launches expanded access programme for integrase inhibitor
• New data shed light on poor outcome in SMART study
• Researchers launch hunt for people who control HIV without drugs
• Single-dose nevirapine not jeopardising mother's treatment, large Zambian study reports
• Anal cancer increases in French HIV cohort, despite use of antiretroviral therapy
• Ranbaxy presents bioequivalence data on two paediatric fixed dose triple combination tablets
• Oral solution of tipranavir/ritonavir shows promise for treatment-experienced kids
• Abacavir/3TC backbone proves most durable for children over five years
• Mixed results on ELISPOT TB testing in resource-limited settings
• Circumcision could have beneficial effect regardless of change in condom use
• Anti-herpes therapy reduces genital and plasma HIV viral load in women not taking HIV therapy
• Sexually transmitted infections increase risk of HIV transmission in serodiscordant couples - but don't fully explain high infection rates
• High rates of TB after beginning ART in Africa — but decreases observed over time
• US-led war on drugs 'inadvertently fuelling HIV epidemic'
• High prevalence of cancerous and pre-cancerous cervical cell changes in HIV-positive women in Zambian study
• Kaletra monotherapy - more encouraging results
• Darunavir/ritonavir superior virologically and immunologically to comparator drugs over one year
• Botswanan isoniazid preventative therapy trial screens out large numbers of people who are already ill
• Two-class ART just as good as three-class in the long-term, and has fewer side-effects
• ‘Opinion leader’ campaign in young black gay men achieves significant reductions in unsafe sex
• First hint that PrEP might work in humans sparks debate on provision
• Selenium improves ART response in Nigerian randomised study
• Very low CD4, rural care, linked to higher risk of death on ARVs in African studies
• Randomised trial of food supplementation in food insecure patients ART inconclusive
• Sexual risk-taking may be associated with MRSA in HIV-positive individuals
• Brain problems and peripheral neuropathy under-diagnosed in Asia and the Pacific
• Abbott cuts lopinavir price to $2200 for middle-income countries; new tablet marketed as Aluvia
• `Put power to prevent HIV in the hands of women`, Bill and Melinda Gates tell AIDS Conference opening
• Abbott cuts lopinavir price to $2200 for middle-income countries; new tablet marketed as Aluvia